Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Equivalents (2018 - 2025)

Arcturus Therapeutics Holdings' Cash & Equivalents history spans 8 years, with the latest figure at $230.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.58% year-over-year to $230.9 million; the TTM value through Dec 2025 reached $230.9 million, down 2.58%, while the annual FY2025 figure was $230.9 million, 2.58% down from the prior year.
  • Cash & Equivalents reached $230.9 million in Q4 2025 per ARCT's latest filing, up from $180.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $466.8 million in Q1 2021 to a low of $180.4 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $301.0 million, with a median of $290.2 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 684.99% in 2021, then plummeted 42.57% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $370.5 million in 2021, then increased by 5.77% to $391.9 million in 2022, then dropped by 25.49% to $292.0 million in 2023, then fell by 18.83% to $237.0 million in 2024, then dropped by 2.58% to $230.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Cash & Equivalents are $230.9 million (Q4 2025), $180.4 million (Q3 2025), and $196.5 million (Q2 2025).